These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 25168947)

  • 61. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.
    Levi MM; Eerenberg E; Löwenberg E; Kamphuisen PW
    Neth J Med; 2010 Feb; 68(2):68-76. PubMed ID: 20167958
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reversal Agents for the Direct Oral Anticoagulants.
    Ansell JE
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1085-98. PubMed ID: 27637309
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study.
    Lorenz R; Kienast J; Otto U; Kiehl M; Schreiter D; Haertel S; Barthels M
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):565-70. PubMed ID: 17762533
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal.
    Taberner DA; Thomson JM; Poller L
    Br Med J; 1976 Jul; 2(6027):83-5. PubMed ID: 776348
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reversal of novel oral anticoagulants in patients with major bleeding.
    Siegal DM; Cuker A
    J Thromb Thrombolysis; 2013 Apr; 35(3):391-8. PubMed ID: 23389753
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB.
    Pagano MB; Foroutan F; Goel R; Allen ES; Cushing MM; Garcia DA; Hopkins CK; Klein K; Raval JS; Cohn CS
    Transfusion; 2022 Aug; 62(8):1652-1661. PubMed ID: 35834523
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
    Sørensen B; Johansen P; Nielsen GL; Sørensen JC; Ingerslev J
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):469-77. PubMed ID: 12851533
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Analysis of anticoagulation reversal survey (ARES).
    Rowe AS; Dietrich S; Hamilton LA
    Hosp Pract (1995); 2020 Aug; 48(3):123-127. PubMed ID: 32295428
    [TBL] [Abstract][Full Text] [Related]  

  • 72. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Is the administration of prothrombin concentrate in heart infarct always absolutely contraindicated?].
    Schricker KT; Haasis R
    Med Klin; 1972 Jun; 67(24):841-5. PubMed ID: 5070409
    [No Abstract]   [Full Text] [Related]  

  • 74. New Oral Anticoagulants and Their Reversal.
    Pinto I; Giri A; Arshad U; Gajra A
    Curr Drug Saf; 2015; 10(3):208-16. PubMed ID: 25877809
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective.
    Unold D; Tormey CA
    Arch Pathol Lab Med; 2015 Dec; 139(12):1568-75. PubMed ID: 26619030
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
    Ogawa S; Szlam F; Ohnishi T; Molinaro RJ; Hosokawa K; Tanaka KA
    Thromb Haemost; 2011 Dec; 106(6):1215-23. PubMed ID: 22071880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
    van Aart L; Eijkhout HW; Kamphuis JS; Dam M; Schattenkerk ME; Schouten TJ; Ploeger B; Strengers PF
    Thromb Res; 2006; 118(3):313-20. PubMed ID: 16182346
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of bleeding complications in the anticoagulated patient.
    Bhagirath VC; O'Malley L; Crowther MA
    Semin Hematol; 2011 Oct; 48(4):285-94. PubMed ID: 22000094
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical use of human prothrombin complexes.
    Tullis JL; Melin M; Jurigian P
    N Engl J Med; 1965 Sep; 273(13):667-74. PubMed ID: 5827030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.